# Open-label Pilot Evaluating Renal Lesions w/ Contrast-enhaced US in Patients w/ Renal Cancer

> **NCT01751529** · EARLY_PHASE1 · COMPLETED · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 48 (actual)

## Conditions studied

- Kidney Cancer

## Interventions

- **PROCEDURE:** Contrast-enhanced Ultrasound
- **DRUG:** Perflutren lipid

## Key facts

- **NCT ID:** NCT01751529
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2017-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01751529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01751529, "Open-label Pilot Evaluating Renal Lesions w/ Contrast-enhaced US in Patients w/ Renal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01751529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*